US 10935554
Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
granted A61KA61K49/0008
Quick answer
US patent 10935554 (Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 5
- CPC classes
- A61K, A61K49/0008